Summary of COVID-19 lopinavir/ritonavir studies

199 patient lopinavir/ritonavir late treatment RCT: 23% lower mortality (p=0.39), 29% greater improvement (p=0.19), and 4% improved viral clearance (p=1).
RCT 199 hospitalized COVID-19 patients showing no significant difference with lopinavir-ritonavir treatment. 28-day mortality was lower in the treatment group, without statistical significance. 3 treatment patients died within 24 hours after randomization and did not receive lopinavir-ritonavir. No significant difference was found in viral RNA load over time between the groups.
May 2020, New England J. Medicine, http://www.nejm.org/doi/10.1056/NEJMoa2001282, https://c19p.org/cao4

2. Yan et al., Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

120 patient lopinavir/ritonavir late treatment study: 40% improved viral clearance (p=0.01).
Retrospective 120 hospitalized non-critically ill COVID-19 patients showing that early administration of lopinavir/ritonavir was associated with shorter duration of SARS-CoV-2 RNA shedding.
May 2020, European Respiratory J., https://publications.ersnet.org/lookup/doi/10.1183/13993003.00799-2020, https://c19p.org/yan8

3. Di Castelnuovo et al., Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

2,972 patient lopinavir/ritonavir late treatment study: 6% lower mortality (p=0.52).
Retrospective 3,451 hospitalized COVID-19 patients in Italy showing higher mortality with darunavir/cobicistat.
Jun 2021, Frontiers in Medicine, https://www.frontiersin.org/articles/10.3389/fmed.2021.639970/full, https://c19p.org/dicastelnuovo3lpv

4. SOLIDARITY Trial Consortium et al., Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results

2,771 patient lopinavir/ritonavir late treatment RCT: no change in mortality (p=1) and 2% higher ventilation (p=0.89).
WHO SOLIDARITY open-label RCT showing no significant difference in outcomes with lopinavir/ritonavir treatment.
Oct 2020, SOLIDARITY Trial Consortium, NEJM, https://www.nejm.org/doi/full/10.1056/NEJMoa2023184, https://c19p.org/solidaritylpv

5. Ader et al., An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial

296 patient lopinavir/ritonavir late treatment RCT: 36% higher mortality (p=0.39) and 26% improved viral clearance (p=0.65).
Early terminated very late stage (95% on oxygen at baseline) DISCOVERY trial showing no significant differences with lopinavir/ritonavir.
Oct 2020, medRxiv, https://www.medrxiv.org/content/10.1101/2022.02.16.22271064, https://c19p.org/discoverylpv

6. Zhou et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

137 patient lopinavir/ritonavir late treatment study: 10% slower viral clearance (p=0.06).
Retrospective 191 hospitalized COVID-19 patients in China showing no significant difference in viral clearance with lopinavir/ritonavir.
Mar 2020, The Lancet, https://www.sciencedirect.com/science/article/pii/S0140673620305663, https://c19p.org/zhou24

7. Değirmenci et al., Is vitamin D level important in pregnant women with COVID-19?

125 patient lopinavir/ritonavir late treatment study: 136% higher hospitalization (p=0.43).
Retrospective 125 pregnant women hospitalized with COVID-19 in Turkey, showing no significant difference in hospitalization length with HCQ, and longer hospitalization with lopinavir/ritonavir use.
Jul 2024, J. Controversies in Obstetrics & Gynecology and Pediatrics, http://journal-jcogp.com/Publication/DisplayArticle/27358, https://c19p.org/degirmencihlpv

8. Wen et al., The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019

117 patient lopinavir/ritonavir late treatment study: 21% slower viral clearance (p=0.008).
Retrospective 178 hospitalized COVID-19 patients in China
Jul 2020, Zhonghua Nei Ke Za Zhi, https://pubmed.ncbi.nlm.nih.gov/32388937/, https://c19p.org/wen4

9. Labhardt et al., Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

318 patient lopinavir/ritonavir prophylaxis RCT: 630% higher progression (p=0.02) and 40% fewer symptomatic cases (p=0.17).
Open-label, cluster-randomized RCT 318 asymptomatic close contacts in Switzerland and Brazil showing no statistically significant difference in symptomatic COVID-19 at 21 days with LPV/r prophylaxis. The mid-trial changes in allocation and 10-month recruitment window introduces potential calendar-time confounding - e.g., if community incidence fell over time, this may over-represent lower-risk weeks in the LPV/r arm, thereby overestimating efficacy. Authors reports 2 hospitalizations but do not specify which group the patients were in.
Dec 2021, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537021004697, https://c19p.org/labhardt

10. Kokturk et al., The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients

1,500 patient lopinavir/ritonavir late treatment study: 118% higher mortality (p=0.38).
Retrospective 1,500 hospitalized late stage (median SaO2 87.7) patients in Turkey, showing no significant difference in mortality with treatment.
Apr 2021, Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S0954611121001396, https://c19p.org/kokturklpv

11. Wong et al., Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study

933 patient lopinavir/ritonavir early treatment study: 96% lower hospital discharge (p<0.0001) and 96% worse recovery (p<0.0001).
Retrospective 933 pediatric COVID-19 patients in Hong Kong showing worse outcomes with early lopinavir/ritonavir (LPV/r) use.
Apr 2022, Pediatric Drugs, https://link.springer.com/10.1007/s40272-022-00500-7, https://c19p.org/wong7

12. Horby et al., Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

5,040 patient lopinavir/ritonavir late treatment RCT: 3% higher mortality (p=0.6), 15% higher ventilation (p=0.15), and 2% lower hospital discharge (p=0.53).
RCT with 1,616 hospitalized COVID-19 patients showing no significant differences with lopinavir-ritonavir treatment compared to usual care.
Oct 2020, The Lancet, https://www.sciencedirect.com/science/article/pii/S0140673620320134, https://c19p.org/horby2

13. Lowe et al., Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

120 patient lopinavir/ritonavir early treatment RCT: 200% higher hospitalization (p=1) and 7% improved viral clearance (p=0.56).
240 patient RCT comparing favipiravir, favipiravir + LPV/r, LPV/r, and placebo, showing improved viral clearance with favipiravir, but no significant difference for LPV/r. Efficacy was lower in the combined favipiravir + LPV/r arm, where plasma levels of favipiravir were lower. Favipiravir 1800mg twice daily on day 1 followed by 400mg four times daily on days 2-7.
Feb 2022, PLOS Medicine, https://journals.plos.org/plosone/article?id=10.1371/journal.pmed.1004120, https://c19p.org/lowelpv

14. Huang et al., No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

65 patient lopinavir/ritonavir early treatment RCT: 6% longer hospitalization (p=0.68), 33% faster recovery (p=0.32), 18% faster improvement (p=0.07), and 15% slower viral clearance (p=0.41).
RCT 101 mild to moderate COVID-19 patients showing no significant difference in antiviral effectiveness among three treatment regimens: ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha.
Jul 2020, Frontiers in Pharmacology, https://www.frontiersin.org/article/10.3389/fphar.2020.01071/full, https://c19p.org/huang17

15. Reis et al., Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial

471 patient lopinavir/ritonavir late treatment RCT: 86% higher mortality (p=1) and 16% higher hospitalization (p=0.72).
Early terminated RCT in Brazil showing no significant differences with lopinavir/ritonavir treatment.
Apr 2021, JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044, https://c19p.org/reislpv

16. Kaizer et al., Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial

446 patient lopinavir/ritonavir late treatment RCT: 203% higher mortality (p=0.49), 20% higher hospitalization (p=0.78), and 3% worse recovery (p=0.88).
RCT 437 non-hospitalized COVID-19 patients showing no significant differences with lopinavir/ritonavir (LPV/r) treatment.
Mar 2023, Int. J. Infectious Diseases, https://www.sciencedirect.com/science/article/pii/S1201971222006658, https://c19p.org/kaizer

17. Li et al., Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial

51 patient lopinavir/ritonavir late treatment RCT: 100% higher progression (p=0.46) and 3% faster viral clearance (p=0.84).
RCT 86 mild/moderate COVID-19 patients showing no significant difference in outcomes with lopinavir/ritonavir or arbidol compared to control.
Dec 2020, Med, https://www.sciencedirect.com/science/article/pii/S2666634020300015, https://c19p.org/li44

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0